Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating activities
Net loss	$ (52,286)	$ (175,767)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	21,953	33,734
Stock-based compensation expense	9,138	(326)
Change in fair value of warrants and contingent liabilities	13,370	(1,170)
Deferred tax benefit	(343)	(926)
Provision for excess and obsolete inventory	180	3,913
Change in third party payor reserves	607	(9,745)
Gain on sale of assets	0	(1,677)
Gain on debt forgiveness	0	(2,750)
Impairment loss	0	10,402
Other	3,630	2,406
Change in operating assets and liabilities:
Accounts receivable	(5,421)	10,263
Inventory	(2,585)	975
Accounts payable and accrued expenses	(20,461)	(46,953)
Other assets and liabilities	3,722	(2,526)
Net cash used in operating activities	(28,496)	(180,147)
Investing activities
Proceeds from maturities of marketable securities	41,060	17,765
Purchases of marketable securities	(66,302)	(47,670)
Purchases of property and equipment	(5,491)	(5,250)
Proceeds from sales of marketable securities	601	0
Consideration on escrow paid for Legacy GeneDx acquisition	0	(12,144)
Proceeds from sales of assets	0	4,034
Development of internal-use software assets	0	(461)
Net cash used in investing activities	(30,132)	(43,726)
Financing activities
Proceeds from offerings, net of issuance costs	46,496	143,002
Exercise of stock options	394	285
Issuance of stock pursuant to employee stock purchase plan	497	0
Long-term debt principal payments	(497)	(2,000)
Finance lease payoff and principal payments	(2,728)	(3,598)
Proceeds from long-term debt	0	48,549
Net cash provided by financing activities	44,162	186,238
Net decrease in cash, cash equivalents and restricted cash	(14,466)	(37,635)
Cash, cash equivalents and restricted cash, at beginning of year	100,668	138,303
Cash, cash equivalents and restricted cash, at end of year	86,202	100,668
Supplemental disclosures of cash flow information
Stock consideration paid pursuant to exercise of Perceptive warrant	12,586	0
Cash paid for interest	6,677	3,041
Purchases of property and equipment in accounts payable and accrued expenses	2,597	134
Cash paid for taxes	1,167	1,465
Assets acquired under capital leases obligations	689	0
Issuance of common stock for first Milestone Payment	0	6,692
Lease liability from obtaining right-of-use asset	$ 0	$ 637